Compound MoA and potential cytotoxic effects deciphered thanks to immunoassays and cell viability assay
The attrition of drug molecules occurs at various stages in the development process, and most early-phase failures are attributed to safety and toxicity issues. Considering the economic impact of early project termination, the biggest challenge comes from selecting the most potent and selective drug compounds while assessing their potential toxic side effects.
In this application note, you’ll discover how to easily combine AlphaLISA®, HTRF®, or AlphaLISA® SureFire® Ultra™ immunoassays with the ATPlite™ 1step cell viability assay to simultaneously, and in a single sample, study the efficacy of drug compounds on disease pathways while identifying possible cytotoxic effects.
